RBC Capital Reiterates Outperform on Cormedix, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Cormedix (NASDAQ:CRMD) and maintained a $9 price target.
August 15, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Cormedix and maintained a $9 price target.
The reiteration of an Outperform rating and the maintenance of a $9 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100